Immix Biopharma

Recent news

• Rating change
  Morgan Stanley Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/3/26
• Rating change
  BofA Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating
  Market Newswire · 2026/8/14
• Rating change
  Citizens JMP Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $23
  Market Newswire · 2026/3/9
• A Quick Look at Today's Ratings for Immix Biopharma(IMMX.US), With a Forecast Between $24 to $30
  Market Newswire · 2026/9/30
• Rating change
  Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $15
  Market Newswire · 2026/3/28
• Rating change
  Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $15
  Market Newswire · 2026/8/12
• LifeSci Capital Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $26
  Market Newswire · 2026/9/10
• Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26
  Market Newswire · 2026/10/1
• Rating change
  Morgan Stanley Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $20
  Market Newswire · 2026/3/25
• Rating change
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $15
  Market Newswire · 2026/3/27
• Rating change
  BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27
  Market Newswire · 2026/6/18
• Rating change
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $25
  Market Newswire · 2026/8/10
• Rating change
  LifeSci Capital Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $19
  Market Newswire · 2026/6/17
• Rating change
  Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21
  Market Newswire · 2026/7/22
• LifeSci Capital Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26
  Market Newswire · 2026/9/13
• Rating change
  Morgan Stanley Maintains Immix Biopharma(IMMX.US) With Buy Rating, Cuts Target Price to $19
  Market Newswire · 2026/8/11
• Rating change
  H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $20
  Market Newswire · 2026/5/22
• Rating change
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
  TipRanks · 2026/5/27
• Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Raises Target Price to $26
  Market Newswire · 2026/9/15
• Rating change
  Needham Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $21
  Market Newswire · 2026/8/10

Headlines are aggregated automatically and are not independently verified or edited by our team.